BeiGene, Ltd. (NASDAQ:BGNE) Insider Xiaodong Wang Sells 40,468 Shares

BeiGene, Ltd. (NASDAQ:BGNE) insider Xiaodong Wang sold 40,468 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $190.10, for a total transaction of $7,692,966.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

BeiGene Stock Up 4.3 %

Shares of BGNE opened at $215.00 on Friday. The stock has a 50 day moving average price of $212.42 and a 200 day moving average price of $184.46. BeiGene, Ltd. has a one year low of $126.97 and a one year high of $248.16. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The stock has a market capitalization of $20.94 billion, a price-to-earnings ratio of -26.09 and a beta of 0.63.

BeiGene (NASDAQ:BGNE) last released its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. BeiGene’s quarterly revenue was up 28.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.01 EPS. Equities research analysts forecast that BeiGene, Ltd. will post -5.38 earnings per share for the current fiscal year.

Institutional Trading of BeiGene

A number of hedge funds have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in shares of BeiGene during the 3rd quarter worth approximately $1,614,000. Quantinno Capital Management LP purchased a new position in BeiGene during the third quarter worth approximately $295,000. Point72 Asset Management L.P. lifted its position in BeiGene by 74.9% during the third quarter. Point72 Asset Management L.P. now owns 667,166 shares of the company’s stock worth $149,785,000 after buying an additional 285,784 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in BeiGene during the third quarter worth $67,000. Finally, Erste Asset Management GmbH purchased a new stake in BeiGene in the 3rd quarter valued at $4,478,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. raised their target price on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, October 22nd. Citigroup raised their price objective on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a report on Thursday, August 8th. StockNews.com downgraded BeiGene from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities started coverage on shares of BeiGene in a research note on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price target on the stock. Finally, TD Cowen upped their price objective on shares of BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $247.07.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.